<DOC>
	<DOCNO>NCT00722930</DOCNO>
	<brief_summary>To evaluate complete clinical response rate accord International Working Group criteria consolidation treatment 90Y-ibritumomab tiuxetan ( ZevalinÂ® ) patient high-risk follicular lymphoma either partial complete response R-CHOP induction chemotherapy</brief_summary>
	<brief_title>Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction High Risk Patients According Follicular Lymphoma International Prognostic Index ( FLIPI ) With Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signature write informed consent subject his/her legal representative initiation trial specific procedure . Patients old 18 . Histologic diagnosis CD20+ , grade 13a follicular lymphoma per WHO classification . Highrisk patient accord FLIPI initiation induction chemotherapy . Stage IIIV prior initiation induction treatment , stage patient grade 3 follicular lymphoma . Complete partial response induction scheme . ECOG scale performance status 0 2 . Life expectancy great 3 month . In woman childbearing age , use reliable contraceptive method . A suitable bone marrow reserve : Lower 25 % Bone marrow infiltration lymphoma . Hb 10 g/dL . PMN leukocytes 1,500 cel/mm3 , platelets 100,000/mm3 Suitable hepatic , renal cardiac function : creatinine &lt; 2,5 x UNL ( upper normality limit ) . bilirubin ALT/AST &lt; 2,5 x UNL Patients objective clinical response induction chemotherapy . &gt; 25 % bone marrow infiltration follow induction chemotherapy . Platelets &lt; 100,000 radioimmunotherapy . Severe and/or uncontrolled concomitant disease : Hepatic , renal , cardiovascular , neurological metabolic disease . Cardiac failure , ischemic cardiopathy , ischemic cardiopathy history myocardial infarction angor , major ventricular arrhythmia . Positive regard HBV , HCV , HIV . Active acute chronic infection . Social , psychic geographic disability satisfy treatment scheme . Pregnant and/or breastfeed woman , adult patient childbearing age use safe birth control device throughout study treatment least 12 month thereafter . Known suspect hypersensitivity , confirm suspected adverse reaction study drug relate compound ( Rituximab , Ibritumomab tiuxetan , history sensitivity murine protein , dexametasone , cyclophosphamide anthracyclines , cytarabine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>High-risk FLIPI</keyword>
	<keyword>R-CHOP</keyword>
	<keyword>GOTEL</keyword>
	<keyword>Partial</keyword>
	<keyword>Complete</keyword>
	<keyword>Response</keyword>
	<keyword>Induction</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>